Abstract
Sensitivities to recombinant human tumor necrosis factor-α (TNF-α) and chemotherapeutic agents (cisplatin, peplomycin, methotrexate) were evaluated in 20 tumor cells of head and neck squamous cell carcinomas, using a dye uptake method. Also, numbers of TNF receptors of these tumor cells were measured by Scatchard plot analysis. There was no relationship between the number of TNF-α receptors and the sensitivity to TNF-α. Furthermore, there was no correlation between the sensitivity to TNF-α and that to chemotherapeutic drugs, nor between the sensitivity to TNF-α and the clinical response to chemotherapy including of cisplatin and peplomycin. The sensitivity to TNF-α was higher in poorly differentiated carcinomas than in well differentiated ones.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- BSA:
-
Bovine serum albumin
- CDDP:
-
Cisplatin
- 5-Fu:
-
5-fluorouracil
- IC50:
-
Inhibition concentration 50
- MTX:
-
Methotrexate
- PLM:
-
Peplomycin
- TNF-α :
-
Tumor necrosis factor-α
References
Sone S, Mutsuura S, Ishii K, Shirahama T, Tsubura E. In vitro cytotoxicity to various human tumor cell lines of a tumor cytotoxic factor(s) produced by human alveolar macrophages. Jpn J Cancer Res (Gann) 1984; 75: 920–8.
Kull FC JR, Jacobs S, Cuatrecasas P. Cellular receptor for125I-labeled tumor necrosis factor: Specific binding, affinity labeling, and relationship to sensitivity. Proc Natl Acad Sci USA 1985; 82: 5756–60.
Watanabe N, Niitsu Y, Neda H, Sone H, Yamauchi N, Maeda M, Urushizaki I. Cytocidal mechanism of TNF: Effects of lysosomal enzyme and hydroxyl radical inhibitors on cytotoxicity. Immunopharmacol Immunotoxicol 1988: 10: 109–16.
Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N, Maeda M, Urushizaki I. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 1988; 48: 2179–83.
Hori K, Ehrke MJ, Mace K, Maccubbin DL, Doyle MJ, Otsuka Y, Mihich E. Effect of recombinant human tumor necrosis factor on the induction murine macorphage tumoricidal activity. Cancer Res 1987; 47: 2793–98.
Collins JL, Kao MS, Patek PQ. Human express natural cytotoxic (NC) cell activity that is similar to murine NC cell activity. J Immunol 1987; 138: 4180–4.
Watanabe N, Niitsu Y, Neda H, Sone H, Yamauchi N, Umetsu T, Urushizaki I. Antitumor effect of tumor necrosis factor against various primarily cultured human cancer cells. Jpn J Cancer Res (Gann) 1985; 76: 1115–9.
Niitsu Y, Watanaabe N, Sone H, Neda H, Yamauchi N, Maeda M, Urushizaki I. Analysis of the TNF receptor on KYM cells by binding assay and affinity cross-linking. J Biol Res Modifiers 1988; 7: 276–82.
Spriggs D, Imamura K, Rodriguez C, Horiguchi J, Kufe DW. Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc Nalt Acad Sci USA 1987; 84: 6563–6.
Niitsu Y, Watanabe N, Neda H, Yamauchi N, Maeda M, Sone H, Kuriyama H. Induction of synthesis of tumor necrosis factor in human and murine cell lines by exogenous recombinant human tumor necrosis factor. Cancer Research 1988; 48: 5407–10.
Grace H, Wong W, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: Possible protective mechanism. Science 1988; 242: 941–4.
Hudziak RM, Lewis GD, Shalaby MR, Eessalu TE, Aggarwal BB, Ullrich A, Shepard HM. Amplified expression of HER2/ERBB2 oncogene induces resistance to tumor necrosis factorα in NIH3T3 cells. Proc Nalt Acad Sci USA 1988; 85: 5102–6.
Fletcher WH, Shiu WW, Ishida TA, Haviland DL, Ware CF. Resistance to the cytolytic action of lymphotoxin and tumor necrosis factor coincides with the presence of gap junctions uniting target cells. J Immunol 1987; 139: 956–62.
Yamauchi N, Watanabe N, Neda H, Sone H, Umetsu T, Niitsu Y, Urushizaki I. Analysis of cell cycle specificity of TNF by binding assay. Igakuno Ayumi. 1986; 137: 315–6 (in Japanese).
Williamson BD, Carswell EA, Rubin BY, Prendergast IS, Old LJ. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Nalt Acad Sci USA 1983; 80: 5397–401.
Ruggiero V, Travernier J, Fiers W, Baglioni C. Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma. J immunol 1986; 136: 2445–50
Alexander RB, Nelson WG, Coffey DS. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res 1987; 47: 2403–6.
Gapany M, Douglas ED, Schriever C, Burgess R. Tumor necrosis factor and cytotoxic agents: effect on squamous carcinoma lines. Arch Otolaryngol Head and Neck Surg 1990; 116: 436–9.
Douglas ED, Gapany M, Robert CB, Peter VB, Don BH. Tumor necrosis factor and chemotherapeutic agents: potentiation of cytotoxicity with interferon gamma. Arch Otolaryngol Head and Neck Surg 1992; 118: 1168–71.
Yanoma S, Tsukuda M, Kubota A, Sawaki S, Takahashi K, Suzuki K, Watanabe S, Ono T. Anti-tumor activity of TNF by anti-tumor chemotherapeutic agent in these cell lines. BIOTHERAPY 1989; 3: 267–71 (in Japanese).
Regenass U, Muller M, Curschellas E, Matters A. Antitumor effects of tumor necrosis factor in combination with chemotherapeutic agents. Int J Cancer 1987; 39: 266–73.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mochimatsu, I., Tsukuda, M., Furukawa, S. et al. The sensitivity of head and neck squamous cell carcinomas to tumor necrosis factor-α. Biotherapy 6, 239–244 (1993). https://doi.org/10.1007/BF01878352
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01878352